Next Article in Journal
Potential Antidepressant Effects of Scutellaria baicalensis, Hericium erinaceus and Rhodiola rosea
Next Article in Special Issue
Ezetimibe Prevents Ischemia/Reperfusion-Induced Oxidative Stress and Up-Regulates Nrf2/ARE and UPR Signaling Pathways
Previous Article in Journal
Antioxidant and Antitumor Activities of Novel Quercetin-Loaded Electrospun Cellulose Acetate/Polyethylene Glycol Fibrous Materials
Previous Article in Special Issue
Vitamin C Activates the Folate-Mediated One-Carbon Cycle in C2C12 Myoblasts
Open AccessArticle

Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus

1
Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy
2
Department of Clinical and Experimental Biomedical Sciences, University of Florence and Diabetology Unit, Careggi Hospital, 50139 Florence, Italy
*
Authors to whom correspondence should be addressed.
Antioxidants 2020, 9(3), 233; https://doi.org/10.3390/antiox9030233
Received: 12 February 2020 / Revised: 4 March 2020 / Accepted: 9 March 2020 / Published: 11 March 2020
(This article belongs to the Special Issue Modulators of Oxidative Stress: Chemical and Pharmacological Aspects)
Pre-clinical studies suggested potential cardiovascular benefits of dipeptidyl peptidase-4 inhibitors (DPP4i), however, clinical trials showed neither beneficial nor detrimental effects in patients with type 2 diabetes mellitus (T2DM). We examined the effects of DPP4i on several circulating oxidative stress markers in a cohort of 32 T2DM patients (21 males and 11 post-menopausal females), who were already on routine antidiabetic treatment. Propensity score matching was used to adjust demographic and clinical characteristics between patients who received and who did not receive DPP4i. Whole-blood reactive oxygen species (ROS), plasma advanced glycation end products (AGEs), advanced oxidation protein products (AOPP), carbonyl residues, as well as ferric reducing ability of plasma (FRAP) and leukocyte DNA oxidative damage (Fpg sites), were evaluated. With the exception of Fpg sites, that showed a borderline increase in DPP4i users compared to non-users (p = 0.0507), none of the biomarkers measured was affected by DPP4i treatment. An inverse correlation between estimated glomerular filtration rate and AGEs (p < 0.0001) and Fpg sites (p < 0.05) was also observed. This study does not show any major effect of DPP4i on oxidative stress, assessed by several circulating biomarkers of oxidative damage, in propensity score-matched cohorts of T2DM patients. View Full-Text
Keywords: type 2 diabetes; dipeptidyl peptidase-4 inhibitors; biomarkers; oxidative stress type 2 diabetes; dipeptidyl peptidase-4 inhibitors; biomarkers; oxidative stress
Show Figures

Figure 1

MDPI and ACS Style

Bigagli, E.; Luceri, C.; Dicembrini, I.; Tatti, L.; Scavone, F.; Giovannelli, L.; Mannucci, E.; Lodovici, M. Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus. Antioxidants 2020, 9, 233.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop